Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 20/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 20/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 19/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28296797 | 0.75 | SLC6A2 (0.54) | SLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL11771618 | 0.74 | SLC6A2 (0.53) | SLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL26919773 | 0.74 | OPRD1 (0.43) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL15259952 | 0.72 | SLC6A2 (0.67) | SLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL15259776 | 0.72 | SLC6A2 (0.67) | SLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL6641573 | 0.71 | SLC6A2 (0.57) | SLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL31066542 | 0.71 | SLC6A2 (0.47) | SLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL18547184 | 0.71 | SLC6A2 (0.47) | SLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL3284783 | 0.70 | SLC6A2 (0.40) | SLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL22491347 | 0.70 | OPRD1 (0.54) | SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060270649-A1 | AZETIDINE DERIVATIVES, THEIR PREPARATION AND MEDICAMENTS CONTAINING THEM | AVENTIS PHARMA S.A. (FR) | 2006-11-30 | — | — | US | disclosed |
| US-6858603-B2 | Acetindine derivatives, their preparation and medicaments containing them | AVENTIS PHARMA S.A. (FR) | 2005-02-22 | — | — | US | disclosed |
| US-20040235816-A1 | Azetidine derivatives, their preparation and medicaments containing them | AVENTIS PHARMA S.A. (FR) | 2004-11-25 | — | — | US | disclosed |
| US-20030162808-A1 | Acetindine derivatives, their preparation and medicaments containing them | AVENTIS PHARMA S.A. (FR) | 2003-08-28 | — | — | US | disclosed |
| EP-1112251-B1 | AZETIDINE DERIVATIVES, PREPARATION AND MEDICINES CONTAINING THEM | AVENTIS PHARMA SA (FR) | 2003-05-07 | — | — | EP | disclosed |
| US-6518264-B2 | For treatment/prevention of psychoses, other brain disorders, and cardiovascular disorders | AVENTIS PHARMA S.A. (FR) | 2003-02-11 | — | — | US | disclosed |
| US-20020035102-A1 | Azetidine derivatives, their preparation and medicaments containing them | AVENTIS PHARMA S.A. (FR) | 2002-03-21 | — | — | US | disclosed |
| EP-1112251-A1 | AZETIDINE DERIVATIVES, PREPARATION AND MEDICINES CONTAINING THEM | Aventis Pharma S.A. (FR) | 2001-07-04 | — | — | EP | disclosed |
| WO-2000015609-A1 | AZETIDINE DERIVATIVES, PREPARATION AND MEDICINES CONTAINING THEM | AVENTIS PHARMA S.A. (FR) | 2000-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235816-A1 | Azetidine derivatives, their preparation and medicaments containing them | AZI2, ADRA2A, ADRA2C | SLC6A2 452/4885SLC6A4 577/4885SLC6A3 424/4885 |
| US-20060270649-A1 | AZETIDINE DERIVATIVES, THEIR PREPARATION AND MEDICAMENTS CONTAINING THEM | AZI2, QDPR, ADRA2A | SLC6A2 412/4885SLC6A4 534/4885SLC6A3 365/4885 |
| US-20020035102-A1 | Azetidine derivatives, their preparation and medicaments containing them | CYP11B2, AZI2, CYP2C19 | SLC6A2 3344/4885SLC6A4 3073/4885SLC6A3 2998/4885 |
| US-20030162808-A1 | Acetindine derivatives, their preparation and medicaments containing them | ADRA1D, ADRB2, AZI2 | SLC6A2 1014/4885SLC6A4 861/4885SLC6A3 1305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.